SG11202106708VA - Method of predicting for benefit from immune checkpoint inhibition therapy - Google Patents

Method of predicting for benefit from immune checkpoint inhibition therapy

Info

Publication number
SG11202106708VA
SG11202106708VA SG11202106708VA SG11202106708VA SG11202106708VA SG 11202106708V A SG11202106708V A SG 11202106708VA SG 11202106708V A SG11202106708V A SG 11202106708VA SG 11202106708V A SG11202106708V A SG 11202106708VA SG 11202106708V A SG11202106708V A SG 11202106708VA
Authority
SG
Singapore
Prior art keywords
predicting
benefit
immune checkpoint
inhibition therapy
checkpoint inhibition
Prior art date
Application number
SG11202106708VA
Inventor
Patrick Tan
Raghav Sundar
Kie Kyon Huang
Aditi Qamra
Jonathan Goke
Deniz Demircioglu
Original Assignee
Agency Science Tech & Res
Nat Univ Hospital Singapore Pte Ltd
Nat Univ Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res, Nat Univ Hospital Singapore Pte Ltd, Nat Univ Singapore filed Critical Agency Science Tech & Res
Publication of SG11202106708VA publication Critical patent/SG11202106708VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Data Mining & Analysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
SG11202106708VA 2018-12-21 2019-12-20 Method of predicting for benefit from immune checkpoint inhibition therapy SG11202106708VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201811546W 2018-12-21
PCT/SG2019/050629 WO2020130948A1 (en) 2018-12-21 2019-12-20 Method of predicting for benefit from immune checkpoint inhibition therapy

Publications (1)

Publication Number Publication Date
SG11202106708VA true SG11202106708VA (en) 2021-07-29

Family

ID=71102946

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106708VA SG11202106708VA (en) 2018-12-21 2019-12-20 Method of predicting for benefit from immune checkpoint inhibition therapy

Country Status (7)

Country Link
US (1) US20220081723A1 (en)
EP (1) EP3899019A4 (en)
JP (1) JP2022515416A (en)
KR (1) KR20210148077A (en)
CN (1) CN113692449A (en)
SG (1) SG11202106708VA (en)
WO (1) WO2020130948A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116200498A (en) * 2023-03-14 2023-06-02 广州希灵生物科技有限公司 Prognosis biomarker for gastric cancer patients and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3090065B1 (en) * 2013-12-30 2019-12-11 Agency For Science, Technology And Research Methods for measuring biomarkers in gastrointestinal cancer
US20170275705A1 (en) * 2014-09-15 2017-09-28 The Johns Hopkins University Biomarkers useful for determining response to pd-1 blockade therapy
ES2767730T3 (en) * 2015-04-30 2020-06-18 Univ Kyoto Method to predict the therapeutic effect of PD-1 / PD-L1 inhibitor using PD-L1 (CD274) abnormality as index
AR105618A1 (en) * 2015-05-29 2017-10-25 Genentech Inc METHODATION OF THE PROMOTER OF THE BINDING TO THE PROGRAMMED DEATH RECEIVER (PD-L1) IN CANCER
SG11201806946VA (en) * 2016-02-16 2018-09-27 Agency Science Tech & Res Epigenomic profiling reveals the somatic promoter landscape of primary gastric adenocarcinoma

Also Published As

Publication number Publication date
CN113692449A (en) 2021-11-23
KR20210148077A (en) 2021-12-07
US20220081723A1 (en) 2022-03-17
WO2020130948A1 (en) 2020-06-25
EP3899019A4 (en) 2022-10-05
EP3899019A1 (en) 2021-10-27
JP2022515416A (en) 2022-02-18

Similar Documents

Publication Publication Date Title
SG11202105109PA (en) Method for detection of rna
PT3322731T (en) Method of treating cancer using immune checkpoint inhibitor
EP3524689C0 (en) Method for predicting the prognosis of breast cancer patient
IL278967A (en) Biomarkers for determining the effectiveness of immune checkpoint inhibitors
IL267885B (en) Methods and systems for computer-based determining of presence of objects
IL290266A (en) Biomarkers for determining the efficacy of immune checkpoint inhibitors
SG11202006997SA (en) A method of determining a risk of cancer
GB2576553B (en) Method of hologram calculation
SG11201912200YA (en) Method for treating a side effect of immunotherapy
SG11202106708VA (en) Method of predicting for benefit from immune checkpoint inhibition therapy
GB201704115D0 (en) Method of selecting for antibodies
GB2580539B (en) Method for co-processing
SG11202102582TA (en) Method and system of targeting epitopes for neoantigen-based immunotherapy
GB2536492B (en) Method of laying lined pipeline
GB201906201D0 (en) Method for the detection of protate cancer
SG11202105877YA (en) Method of treatment
IL261475A (en) Method of identifying optimal zones for electropulse therapy (variants)
GB201704386D0 (en) Method for identification of sofosbuvir resistant patients
GB201617722D0 (en) Method for determining prognosis of cancer
GB201914079D0 (en) Method of predicting requirement for biologic therapy
SG11202101817UA (en) Methods of inhibition
GB201815409D0 (en) Computer-Implemented methods for predicting psychological therapy outcome
GB201800556D0 (en) Computer-implemented methods for predicting psychological therapy outcome
ZA202001642B (en) Method for the treatment of iron-containing sludge
GB201906199D0 (en) Method for the detection of cancer